Clinical Resveratrol [Discontinued] by OL Olympian Labs Incorporated

INSUFFICIENT RELIABLE EVIDENCE to RATE

• Allergic rhinitis (hay fever). Although there has been interest in using oral hu zhang for allergic rhinitis, there is insufficient reliable information about the clinical effects of hu zhang for this purpose.
• Biliary disorders. Although there has been interest in using oral hu zhang for biliary disorders, there is insufficient reliable information about the clinical effects of hu zhang for this purpose.
• Constipation. Although there has been interest in using oral hu zhang for constipation, there is insufficient reliable information about the clinical effects of hu zhang for this purpose.
• Diabetes. Although there has been interest in using oral hu zhang for diabetes, there is insufficient reliable information about the clinical effects of hu zhang for this purpose.
• Gout. Although there has been interest in using oral hu zhang for gout, there is insufficient reliable information about the clinical effects of hu zhang for this purpose.
• Hepatitis. Although there has been interest in using oral hu zhang for hepatitis, there is insufficient reliable information about the clinical effects of hu zhang for this purpose.
• Menopausal symptoms. Although there has been interest in using oral hu zhang for menopausal symptoms, there is insufficient reliable information about the clinical effects of hu zhang for this purpose.
• Osteoarthritis. Although there has been interest in using oral hu zhang for osteoarthritis, there is insufficient reliable information about the clinical effects of hu zhang for this purpose.
• Rheumatoid arthritis (RA). Although there has been interest in using oral hu zhang for RA, there is insufficient reliable information about the clinical effects of hu zhang for this purpose.
• Unstable angina. Oral hu zhang has only been evaluated in combination with other ingredients; its effect when used alone is unclear. Details: One clinical study in patients hospitalized with unstable angina shows that taking hu zhang granules 7.5 grams and hawthorn granules 5 grams twice daily for 4 weeks, along with conventional therapy, improves quality of life and angina symptom scores, but does not reduce the frequency of angina attacks, when compared with conventional therapy alone (109610).
• Wound healing. Although there has been interest in using topical hu zhang for wound healing, there is insufficient reliable information about the clinical effects of hu zhang for this purpose. More evidence is needed to rate hu zhang for these uses.

(Read more about HU ZHANG)

There is insufficient reliable information available about the safety of hu zhang.

PREGNANCY AND LACTATION:
Insufficient reliable information available; avoid using.

(Read more about HU ZHANG)

ANTICOAGULANT/ANTIPLATELET DRUGS Interaction Rating = Moderate Be cautious with this combination. Severity = High •  Occurrence = Possible •  Level of Evidence = D Theoretically, hu zhang might increase the risk of bleeding when taken with anticoagulant or antiplatelet drugs.  Details Hu zhang contains the constituent resveratrol. Resveratrol seems to have antiplatelet effects (2949,2950,2951,2952,2961,70813,70828,70831,70892,70968,71106).

CARBAMAZEPINE (Tegretol) Interaction Rating = Minor Be watchful with this combination. Severity = Mild •  Occurrence = Possible •  Level of Evidence = D Theoretically, hu zhang might increase the effects and adverse effects of carbamazepine.  Details In animals, blood and tissue levels of carbamazepine were increased when given in combination with hu zhang. It is thought that increased levels of carbamazepine are due to cytochrome P450 3A4 (CYP3A4) inhibition (101418). This interaction has not been reported in humans.

CYTOCHROME P450 1A1 (CYP1A1) SUBSTRATES Interaction Rating = Moderate Be cautious with this combination. Severity = Moderate •  Occurrence = Possible •  Level of Evidence = D Theoretically, hu zhang might increase levels of drugs metabolized by CYP1A1.  Details Hu zhang contains the constituent resveratrol. In vitro research shows that resveratrol might inhibit the CYP1A1 enzyme (70862,70811). This interaction has not been reported in humans.

CYTOCHROME P450 1A2 (CYP1A2) SUBSTRATES Interaction Rating = Moderate Be cautious with this combination. Severity = Moderate •  Occurrence = Possible •  Level of Evidence = D Theoretically, hu zhang might increase levels of drugs metabolized by CYP1A2.  Details Hu zhang contains the constituent resveratrol. In vitro research shows that resveratrol might inhibit the CYP1A2 enzyme (21733). This interaction has not been reported in humans.

CYTOCHROME P450 1B1 (CYP1B1) SUBSTRATES Interaction Rating = Moderate Be cautious with this combination. Severity = Moderate •  Occurrence = Possible •  Level of Evidence = D Theoretically, hu zhang might increase levels of drugs metabolized by CYP1B1.  Details Hu zhang contains the constituent resveratrol. In vitro research shows that resveratrol might inhibit the CYP1B1 enzyme (70834). This interaction has not been reported in humans.

CYTOCHROME P450 2C19 (CYP2C19) SUBSTRATES Interaction Rating = Moderate Be cautious with this combination. Severity = Moderate •  Occurrence = Possible •  Level of Evidence = D Theoretically, hu zhang might increase levels of drugs metabolized by CYP2C19.  Details Hu zhang contains the constituent resveratrol. In vitro research shows that resveratrol might inhibit the CYP2C19 enzyme (70896). This interaction has not been reported in humans.

CYTOCHROME P450 2E1 (CYP2E1) SUBSTRATES Interaction Rating = Moderate Be cautious with this combination. Severity = Moderate •  Occurrence = Possible •  Level of Evidence = D Theoretically, hu zhang might increase levels of drugs metabolized by CYP2E1.  Details Hu zhang contains the constituent resveratrol. In vitro research shows that resveratrol might inhibit the CYP2E1 enzyme (7864,70896). Also, a pharmacokinetic study shows that taking resveratrol 500 mg daily for 10 days prior to taking a single dose of chlorzoxazone 250 mg increases the maximum concentration of chlorzoxazone by about 54%, the area under the curve of chlorzoxazone by about 72%, and the half-life of chlorzoxazone by about 35% (95824). Chlorzoxazone is used as a probe drug for CYP2E1.

CYTOCHROME P450 3A4 (CYP3A4) SUBSTRATES Interaction Rating = Moderate Be cautious with this combination. Severity = Moderate •  Occurrence = Possible •  Level of Evidence = D Theoretically, hu zhang might increase levels of drugs metabolized by CYP3A4.  Details Hu zhang contains the constituent resveratrol. In vitro research shows that resveratrol might inhibit the CYP3A4 enzyme (7864,70896). However, a clinical study in adults with NAFLD found that adding resveratrol 3000 mg daily for 8 weeks did not necessitate dose adjustments to any established medications metabolized by CYP3A4 (91327).

ESTROGENS Interaction Rating = Moderate Be cautious with this combination. Severity = Moderate •  Occurrence = Possible •  Level of Evidence = D Theoretically, hu zhang might competitively inhibit the effects of estrogen replacement therapy.  Details In vitro research shows that hu zhang might have estrogenic activity (13124,16061).

(Read more about HU ZHANG)

General ...There is currently a limited amount of information on the adverse effects of hu zhang.

(Read more about HU ZHANG)